Contents
Editor’s Letter
First 2022 GaBI Journal issue highlights
Letter to Editor
No need for systematic switch studies to demonstrate interchangeability of biosimilars
Review Article
Biotherapeutic products in the European Pharmacopoeia: have all challenges been tackled?
Opinion
Sponsored Article
Structural characterization methods for biosimilars: fit-for-purpose, qualified or validated